In yesterday’s Wall Street session, Kiniksa Pharmaceuticals Ltd. (NASDAQ:KNSA) shares traded at $20.20, up 3.70% from the previous session.
5 analysts cover Kiniksa Pharmaceuticals Ltd. (NASDAQ:KNSA), according to research data. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $32.00 and a low of $20.00, we find $23.00. Given the previous closing price of $19.48, this indicates a potential upside of 18.07 percent. KNSA stock price is now 37.14% away from the 50-day moving average and 46.37% away from the 200-day moving average. The market capitalization of the company currently stands at $1.38B.
The stock has received a hold rating from 0 analysts and a buy rating from 5. Brokers who have rated the stock have averaged $24.60 as their price target over the next twelve months.
With the price target enhanced from $25 to $40, BofA Securities maintained Buy rating for Kiniksa Pharmaceuticals Ltd. (NASDAQ: KNSA).
In other news, Quart Barry D, Director sold 21,959 shares of the company’s stock on Nov 29. The stock was sold for $354,638 at an average price of $16.15. Upon completion of the transaction, the Director now directly owns 0 shares in the company, valued at $0.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 07, CHIEF MEDICAL OFFICER Paolini John F. sold 28,357 shares of the business’s stock. A total of $430,459 was realized by selling the stock at an average price of $15.18. This leaves the insider owning 36,335 shares of the company worth $0.73 million. Insiders disposed of 74,723 shares of company stock worth roughly $1.51 million over the past 1 year. A total of 0.30% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in KNSA stock. A new stake in Kiniksa Pharmaceuticals Ltd. shares was purchased by ENVESTNET ASSET MANAGEMENT INC during the first quarter worth $5,501,000. QUBE RESEARCH & TECHNOLOGIES LTD invested $2,559,000 in shares of KNSA during the first quarter. In the first quarter, ESSEX INVESTMENT MANAGEMENT CO LLC acquired a new stake in Kiniksa Pharmaceuticals Ltd. valued at approximately $2,407,000. MASSACHUSETTS FINANCIAL SERVICES CO /MA/ acquired a new stake in KNSA for approximately $1,675,000. TEJARA CAPITAL LTD purchased a new stake in KNSA valued at around $980,000 in the second quarter. In total, there are 207 active investors with 45.50% ownership of the company’s stock.
On Wednesday morning Kiniksa Pharmaceuticals Ltd. (NASDAQ: KNSA) stock kicked off with the opening price of $19.48. During the past 12 months, Kiniksa Pharmaceuticals Ltd. has had a low of $9.63 and a high of $20.00. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 6.30, and a quick ratio of 5.70. The fifty day moving average price for KNSA is $14.86 and a two-hundred day moving average price translates $13.83 for the stock.
The latest earnings results from Kiniksa Pharmaceuticals Ltd. (NASDAQ: KNSA) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at $0.21, beating analysts’ expectations of -$0.17 by 0.38. This compares to -$0.36 EPS in the same period last year. The net profit margin was 83.10% and return on equity was 59.30% for KNSA. The company reported revenue of $48.34 million for the quarter, compared to $32.19 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 50.19 percent. For the current quarter, analysts expect KNSA to generate $62.2M in revenue.
Kiniksa Pharmaceuticals Ltd.(KNSA) Company Profile
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that completed Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
